Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of Y-2 sublingual tablet in acute ischemic stroke
ChiCTR2100043132Phase 3Recruiting
- Sponsor
- Peking University Third Hospital
- Start
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in ischemic stroke comparing Y-2 sublingual tablets with Y-2 placebo (2 arms). Primary endpoint: modified Rankin Scale (mRS) score. Started Feb 2021; status: recruiting.
02
Drugs
edaravone dexborneol
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on ChiCTR2100043132.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100043132.